Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05762107 · ClinicalTrials.gov registry record · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
A Phase 2 study of Type 1 Diabetes Mellitus With Hypoglycemia, sponsored by Zucara Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 186
- Enrollment target
- 20
- Study locations
NCT05762107: Recruiting Phase 2 study of Type 1 Diabetes Mellitus With Hypoglycemia, sponsored by Zucara Therapeutics.
NCT05762107 is a Phase 2 study of Type 1 Diabetes Mellitus With Hypoglycemia that is actively recruiting participants, run by Zucara Therapeutics. The registered enrollment target is 186 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05762107, a Phase 2 study of Type 1 Diabetes Mellitus With Hypoglycemia, is actively recruiting participants, sponsored by Zucara Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 186 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to learn about the effect of the study drug (ZT-01) on low blood sugar (hypoglycemia) in adults with type 1 diabetes (T1D) who have been having low blood sugars ("hypos") at night. ZT-01 increases the amount of a hormone called glucagon during low blood sugar, and this may help prevent the occurrence of hypos. The main questions this trial aims to answer are whether ZT-01 lowers the number of hypos happening at night, and what its effects are on blood sugar levels. The safety of ZT-01 will also be measured. Participants will be asked to wear a study-provided continuous glucose monitor (CGM) during two 4-week periods when they will self-inject the study drug before bed. They will get ZT-01 at one of three dose levels during one period, and placebo (which looks like the study drug but doesn't contain the active ingredient) during the other. Neither the participant nor the study site will know what they are receiving during each treatment period or see data from the CGM. The participant will continue to use their usual methods of measuring blood sugar (including their personal CGM) and giving insulin during the study. The participant will be asked to complete a short diary each evening, and will be asked to upload the CGM data to a study phone every day. If a participant uses their own CGM and is willing to share information on how often they have low blood sugar with the study site at the first visit to see if they meet study entry requirements, they will have 6 study visits, 2 study phone calls, and be in the study for about 16 weeks. If they don't use CGM or don't want to share their information, then they will be asked to wear a study CGM for an extra 4 weeks to find out how many low blood sugars they have, and will have an extra visit. Study participants will be asked to give blood and urine for testing to see whether they meet the requirements to enter the study, and at the start and end of each treatment period to see if the
Primary Outcome
Rate of nocturnal (midnight to 06:00 AM) hypoglycemic events (glucose \<54 mg/dL) lasting at least 15 minutes, compared to placebo
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ZT-01, 7 mg
- DRUG ZT-01, 15 mg
- DRUG ZT-01, 22 mg
Study Locations (20)
Florida
- East Coast Institute for Research LLC - Jacksonville
- Suncoast Clinical Research - New Port Richey
- Hanson Diabetes Center - Port Charlotte
- Metabolic Research Institute - West Palm Beach
California
- Headlands Research - Escondido
- USC Keck Medicine Eastside Center for Diabetes - Los Angeles
- LCGK Research - San Carlos
Georgia
- Atlanta Diabetes Associates - Atlanta
- Physicians Research Associates LLC - Lawrenceville
- East Coast Institute for Research - Macon
Maryland
- Baltimore VA Medical Center - Baltimore
- MedStar Good Samaritan Hospital - Baltimore
New York
- Albany Medical Center - Albany
- NYC Research Inc. - Long Island City
Indiana
- IU Health University Hospital - Indianapolis
Kansas
- University of Kansas Medical Center - Kansas City
Michigan
- Elite Research Center - Flint
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2023-07-28 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
What NCT05762107 shows while recruiting
NCT05762107 is an interventional study that assigns participants to a tested intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% higher).
The record links to 1 condition, with Type 1 Diabetes Mellitus With Hypoglycemia appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT05762107 names 20 study sites across 11 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT05762107 about?
NCT05762107 is a clinical study titled "A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes". The goal of this clinical trial is to learn about the effect of the study drug (ZT-01) on low blood sugar (hypoglycemia) in adults with type 1 diabetes (T1D) who have been having low blood sugars ("hypos") at night. ZT-01 increases the amount of a hormone called glucagon during low blood sugar, and ...
What is the current status of trial NCT05762107?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 186 participants. The study started on 2023-07-28. Estimated completion is 2027-05.
What conditions does trial NCT05762107 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus With Hypoglycemia.
What interventions are being tested in trial NCT05762107?
The interventions under investigation include: Placebo (DRUG), ZT-01, 7 mg (DRUG), ZT-01, 15 mg (DRUG), ZT-01, 22 mg (DRUG).
Who is sponsoring clinical trial NCT05762107?
This trial is sponsored by Zucara Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05762107 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05762107's enrollment target sits among peer trials
186 357th of 2000 higher than 1,644 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05868668 · 186 participants · NA
Efficacy of Low-intensity Shockwave vs Radial Wave for Treatment of Erectile Dysfunction and Pelvic Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI